tbuckley/cabot-search huggingface dataset:
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Authors: Arun J. Sanyal, Lee M. Kaplan, Juan P. Frias, Bram Brouwers, Qiwei Wu, Melissa K. Thomas, Charles Harris, Nanette C. Schloot, Yu Du, Kieren J. Mather, Axel Haupt, Mark L. Hartman
Journal: Nature Medicine (2024)

Abstract Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively. The primary objective of this substudy was to assess mean relative change from baseline in liver fat (LF) at 24 weeks in participants from that study with metabolic dysfunction-associated steatotic liver disease and ≥10% of LF. Here, in this randomized, double-blind, placebo-controlled trial, participants ( n = 98) were randomly assigned to 48 weeks of once-weekly subcutaneous retatrutide (1, 4, 8 or 12 mg dose) or placebo. The mean relative change from baseline in LF at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), −82.4% (12 mg) and +0.3% (placebo) (all P &lt; 0.001 versus placebo). At 24 weeks, normal LF (&lt;5%) was achieved by 27% (1 mg), 52% (4 mg), 79% (8 mg), 86% (12 mg) and 0% (placebo) of participants. LF reductions were significantly related to changes in body weight, abdominal fat and metabolic measures associated with improved insulin sensitivity and lipid metabolism. The ClinicalTrials.gov registration is NCT04881760 .
Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy
Authors: Min Hye Noh, Jin Muk Kang, Alexandra A Miller, Grace Nguyen, Minxin Huang, Ji Seon Shim, Alberto J Bueso-Perez, Sara A Murphy, Kimberly A Rivera-Caraballo, Yoshihiro Otani, Eunju Kim, Seung-Hee Yoo, Yuanqing Yan, Yeshavanth Banasavadi-Siddegowda, Hiroshi Nakashima, E Antonio Chiocca, Balveen Kaur, Zhongming Zhao, Tae Jin Lee, Ji Young Yoo
Journal: Neuro-Oncology (2024)

The FDA approval of oncolytic herpes simplex-1 virus (oHSV) therapy underscores its therapeutic promise and safety as a cancer immunotherapy. Despite this promise, the current efficacy of oHSV is significantly limited to a small subset of patients largely due to the resistance in tumor and tumor microenvironment (TME).
The stimulation of <scp>TH2</scp> cells results in increased <scp>IL</scp>‐5 and <scp>IL</scp>‐13 production via the <scp>H<sub>4</sub></scp> receptor
Authors: Eirini Nikolouli, Susanne Mommert, Damilola Modupe Dawodu, Katrin Schaper‐Gerhardt, Holger Stark, Oliver Dittrich‐Breiholz, Ralf Gutzmer, Thomas Werfel
Journal: Allergy (2024)

Abstract Background Atopic dermatitis (AD) is a chronic inflammatory skin disease resulting in decreased quality of life. Histamine and specifically the H 4 receptor play a key role in the inflammatory process in AD and serve as targets for novel therapeutic approaches. Objective In the present study we aimed to elucidate the immunopathological mechanisms with which the H 4 receptor impacts TH2 cells and contributes to AD pathophysiology. Methods Total CD4 + T cells obtained from healthy or AD individuals and in vitro differentiated TH2 cells were cultured under different conditions and the mRNA expression or protein production of target molecules were determined using quantitative real‐time PCR and ELISA. Results H 4 receptor mRNA expression was upregulated concentration dependent upon IL‐4 stimulation in in vitro differentiated TH2 cells progressively during the differentiation. Transcriptomic analysis of in vitro differentiated TH2 versus TH1 cells revealed that the H 4 receptor among other genes represents one of the highly upregulated genes in TH2 cells. Most importantly, increased amounts of IL‐5 and IL‐13 mRNA expression were detected in in vitro differentiated TH2 cells as well as protein secretion in the presence of histamine or of the H 4 receptor‐selective‐agonist when compared to the untreated control. Conclusion We show for the first time an H 4 receptor dependent upregulation of the pro‐inflammatory cytokines IL‐5 and IL‐13 in human TH2 cells by histamine. This suggests that the blockade of the H 4 receptor may lead to downregulation of these cytokines and amelioration of AD symptoms as reported in first clinical studies.
Right heart failure with left ventricular assist devices: Preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the Heart Failure Association (<scp>HFA</scp>) of the <scp>ESC</scp>
Authors: Stamatis Adamopoulos, Michael Bonios, Tuvia Ben Gal, Finn Gustafsson, Magdy Abdelhamid, Marianna Adamo, Antonio Bayes‐Genis, Michael Böhm, Ovidiu Chioncel, Alain Cohen‐Solal, Kevin Damman, Concetta Di Nora, Shahrukh Hashmani, Loreena Hill, Tiny Jaarsma, Ewa Jankowska, Yury Lopatin, Marco Masetti, Mandeep R. Mehra, Davor Milicic, Brenda Moura, Wilfried Mullens, Sanem Nalbantgil, Chrysoula Panagiotou, Massimo Piepoli, Amina Rakisheva, Arsen Ristic, Rasmus Rivinius, Gianluigi Savarese, Thomas Thum, Carlo Gabriele Tocchetti, Laurens F. Tops, Linda W. Van Laake, Maurizio Volterrani, Petar Seferovic, Andrew Coats, Marco Metra, Giuseppe Rosano
Journal: European Journal of Heart Failure (2024)
Circulating beta‐hydroxybutyrate levels in advanced heart failure with reduced ejection fraction: Determinants and prognostic impact
Authors: Luca Monzo, Jan Kovar, Barry Borlaug, Jan Benes, Martin Kotrc, Katerina Kroupova, Antonin Jabor, Janka Franekova, Vojtech Melenovsky
Journal: European Journal of Heart Failure (2024)
Common and Uncommon Mouse Models of Growth Hormone Deficiency
Authors: Edward O List, Reetobrata Basu, Darlene E Berryman, Silvana Duran-Ortiz, Gabriel Á Martos-Moreno, John J Kopchick
Journal: Endocrine Reviews (2024)

Abstract Mouse models of growth hormone deficiency (GHD) have provided important tools for uncovering the various actions of GH. Nearly 100 years of research using these mouse lines has greatly enhanced our knowledge of the GH/IGF-1 axis. Some of the shared phenotypes of the 5 “common” mouse models of GHD include reduced body size, delayed sexual maturation, decreased fertility, reduced muscle mass, increased adiposity, and enhanced insulin sensitivity. Since these common mouse lines outlive their normal-sized littermates—and have protection from age-associated disease—they have become important fixtures in the aging field. On the other hand, the 12 “uncommon” mouse models of GHD described herein have tremendously divergent health outcomes ranging from beneficial aging phenotypes (similar to those described for the common models) to extremely detrimental features (such as improper development of the central nervous system, numerous sensory organ defects, and embryonic lethality). Moreover, advancements in next-generation sequencing technologies have led to the identification of an expanding array of genes that are recognized as causative agents to numerous rare syndromes with concomitant GHD. Accordingly, this review provides researchers with a comprehensive up-to-date collection of the common and uncommon mouse models of GHD that have been used to study various aspects of physiology and metabolism associated with multiple forms of GHD. For each mouse line presented, the closest comparable human syndromes are discussed providing important parallels to the clinic.
Author Correction: The senescent methylome and its relationship with cancer, ageing and germline genetic variation in humans
Authors: Robert Lowe, Marita G. Overhoff, Sreeram V. Ramagopalan, James C. Garbe, James Koh, Martha R. Stampfer, David H. Beach, Vardhman K. Rakyan, Cleo L. Bishop
Journal: Genome biology (2024)
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
Authors: M.A. Powell, L. Bjørge, L. Willmott, Z. Novák, D. Black, L. Gilbert, S. Sharma, G. Valabrega, L.M. Landrum, M. Gropp-Meier, A. Stuckey, I. Boere, M.A. Gold, Y. Segev, S.E. Gill, C. Gennigens, A. Sebastianelli, M.S. Shahin, B. Pothuri, B.J. Monk, J. Buscema, R.L. Coleman, B.M. Slomovitz, K.L. Ring, T.J. Herzog, M.M. Balas, M. Grimshaw, S. Stevens, D.W. Lai, C. McCourt, M.R. Mirza
Journal: Annals of Oncology (2024)

BackgroundPart 1 of the RUBY trial (NCT03981796) evaluated dostarlimab plus carboplatin-paclitaxel compared with placebo plus carboplatin-paclitaxel in patients with primary advanced or recurrent endometrial cancer. At the first interim analysis, the trial met one of its dual-primary endpoints with statistically significant progression-free survival benefits in the mismatch repair deficient/microsatellite instability–high (dMMR/MSI-H) and overall populations. Overall survival (OS) results are reported from the second interim analysis.Patients and MethodsRUBY is a phase 3, global, double-blind, randomized, placebo-controlled trial. Part 1 of RUBY enrolled eligible patients with primary advanced stage III or IV or first recurrent endometrial cancer who were randomly assigned (1:1) to receive either dostarlimab (500 mg) or placebo, plus carboplatin-paclitaxel every 3 weeks for 6 cycles followed by dostarlimab (1000 mg) or placebo every 6 weeks for up to 3 years. OS was a dual-primary endpoint.ResultsA total of 494 patients were randomized (245 in dostarlimab arm; 249 in placebo arm). In the overall population, with 51% maturity, RUBY met the dual-primary endpoint for OS at this second interim analysis, with a statistically significant reduction in the risk of death (HR = 0.69; 95% CI, 0.54-0.89; P = 0.0020) in patients treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel alone. The risk of death was lower in the dMMR/MSI-H population (HR = 0.32; 95% CI, 0.17-0.63; nominal P = 0.0002) and a trend in favor of dostarlimab was seen in the mismatch repair proficient/microsatellite stable (MMRp/MSS) population (HR = 0.79; 95% CI, 0.60-1.04; nominal P = 0.0493). The safety profile for dostarlimab plus carboplatin-paclitaxel was consistent with the first interim analysis.ConclusionsDostarlimab in combination with carboplatin-paclitaxel demonstrated a statistically significant and clinically meaningful overall survival benefit in the overall population of patients with primary advanced or recurrent endometrial cancer while demonstrating an acceptable safety profile.
Evolutionary ecology of masting: mechanisms, models, and climate change
Authors: Michal Bogdziewicz, Dave Kelly, Davide Ascoli, Thomas Caignard, Francesco Chianucci, Elizabeth E. Crone, Emilie Fleurot, Jessie J. Foest, Georg Gratzer, Tomika Hagiwara, Qingmin Han, Valentin Journé, Léa Keurinck, Katarzyna Kondrat, Ryan McClory, Jalene M. LaMontagne, Ignacio A. Mundo, Anita Nussbaumer, Iris Oberklammer, Misuzu Ohno, Ian S. Pearse, Mario B. Pesendorfer, Giulia Resente, Akiko Satake, Mitsue Shibata, Rebecca S. Snell, Jakub Szymkowiak, Laura Touzot, Rafal Zwolak, Magdalena Zywiec, Andrew J. Hacket-Pain
Journal: Trends in Ecology & Evolution (2024)

Many perennial plants show mast seeding, characterized by synchronous and highly variable reproduction across years. We propose a general model of masting, integrating proximate factors (environmental variation, weather cues, and resource budgets) with ultimate drivers (predator satiation and pollination efficiency). This general model shows how the relationships between masting and weather shape the diverse responses of species to climate warming, ranging from no change to lower interannual variation or reproductive failure. The role of environmental prediction as a masting driver is being reassessed; future studies need to estimate prediction accuracy and the benefits acquired. Since reproduction is central to plant adaptation to climate change, understanding how masting adapts to shifting environmental conditions is now a central question.
Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege
Authors: David Rutkowski, Rachel Scholey, John Davies, Derek Pye, Fiona Blackhall, Richard B Warren, Francisco Jimenez, Christopher E M Griffiths, Ralf Paus
Journal: British Journal of Dermatology (2024)

Abstract Background Inhibitors of epidermal growth factor receptor (EGFRi) or mitogen-activated kinase (MEKi) induce a folliculitis in 75–90% of patients, the pathobiology of which remains insufficiently understood. Objectives To characterize changes in the skin immune status and global transcriptional profile of patients treated with EGFRi; to investigate whether EGFRi affects the hair follicle’s (HF) immune privilege (IP); and to identify early proinflammatory signals induced by EGFRi/MEKi in human scalp HFs ex vivo. Methods Scalp biopsies were taken from patients exhibiting folliculitis treated long term with EGFRi (‘chronic EGFRi’ group, n = 9) vs. healthy scalp skin (n = 9) and patients prior to commencing EGFRi treatment and after 2 weeks of EGFRi therapy (‘acute EGFRi’ group, n = 5). Healthy organ-cultured scalp HFs were exposed to an EGFRi (erlotinib, n = 5) or a MEKi (cobimetinib, n = 5). Samples were assessed by quantitative immunohistomorphometry, RNA sequencing (RNAseq) and in situ hybridization. Results The ‘chronic EGFRi’ group showed CD8+ T-cell infiltration of the bulge alongside a partial collapse of the HF’s IP, evidenced by upregulated major histocompatibility complex (MHC) class I, β2-microglobulin (B2 M) and MHC class II, and decreased transforming growth factor-β1 protein expression. Healthy HFs treated with EGFRi/MEKi ex vivo also showed partial HF IP collapse and increased transcription of human leucocyte antigen (HLA)-A, HLA-DR and B2 M transcripts. RNAseq analysis showed increased transcription of chemokines (CXCL1, CXCL13, CCL18, CCL3, CCL7) and interleukin (IL)-26 in biopsies from the ‘chronic EGFRi’ cohort, as well as increased IL-33 and decreased IL-37 expression in HF biopsies from the ‘acute EGFRi’ group and in organ-cultured HFs. Conclusions The data show that EGFRi/MEKi compromise the physiological IP of human scalp HFs and suggest that future clinical management of EGFRi/MEKi-induced folliculitis requires HF IP protection and inhibition of IL-33.
What is the expected live birth rate per thawed oocyte?
Authors: Raoul Orvieto
Journal: Human Reproduction Update (2024)

Journal Article What is the expected live birth rate per thawed oocyte? Get access Raoul Orvieto Raoul Orvieto Infertility and IVF Institute, Chaim Sheba Medical Center, Ramat Gan, IsraelDepartment of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, IsraelThe Tarnesby-Tarnowski Chair for Family Planning and Fertility Regulation, Faculty of Medical and Health Science, Tel-Aviv University, Tel Aviv, Israel Correspondence address. Infertility and IVF Institute, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel and The Faculty of Medical and Health Science, Tel-Aviv University, Tel Aviv, Israe. E-mail: raoul.orvieto@sheba.health.gov.il https://orcid.org/0000-0002-0865-1196 Search for other works by this author on: Oxford Academic PubMed Google Scholar Human Reproduction Update, dmae015, https://doi.org/10.1093/humupd/dmae015 Published: 10 June 2024 Article history Editorial decision: 24 May 2024 Received: 24 May 2024 Published: 10 June 2024
Progress in Lung Cancer Screening Adoption
Authors: Ilana B. Richman, Cary P. Gross
Journal: JAMA Internal Medicine (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Anesthesia Dose and Delirium—A Picture Coming Into Focus
Authors: Miles Berger, Mark D. Neuman
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biomimetic Nano‐Regulator that Induces Cuproptosis and Lactate‐Depletion Mediated ROS Storm for Metalloimmunotherapy of Clear Cell Renal Cell Carcinoma
Authors: Xiaotong Xu, Huimin Li, Binghua Tong, Weijie Zhang, Xiaofei Wang, Yue Wang, Geng Tian, Zhaowei Xu, Guilong Zhang
Journal: Advanced Healthcare Materials (2024)

Abstract Herein, a ccRCC targeting nanodrug is designed to enhance chemodynamic therapy (CDT) as well as activate cuproptosis and tumor immunotherapy via ccRCC cell membrane modifying CuO@Gd 2 O 3 yolk‐like particles (CGYL) loaded with lactate oxidase (LOx) (mCGYL‐LOx). Benefiting from the homologous targeting effect of Renca cell membranes, the mCGYS‐LOx can be effectively internalized by Renca cells, open the “gate”, and then release LOx and copper (Cu) ions. LOx can catalyze excessive lactate in Renca cells into H 2 O 2 , following that the produced H 2 O 2 is further converted by Cu ions to the highly toxic ·OH, contributing to tumor CDT. Meanwhile, the excessive Cu ions effectively trigger tumor cuproptosis. These synergistic effects induce the release of damage associated molecular patterns (DAMPs) and activate immunogenic cell death (ICD), leading to DC maturation and infiltration of immune effector cells. Moreover, LOx‐mediated lactate consumption downregulates the expression of PD‐L1, crippling tumor immune escape. In addition, the mCGYL‐LOx improves T 1 ‐weighted MRI signal, allowing for accurate diagnosis of ccRCC. This study demonstrates that the mCGYL‐LOx has great potential for improving therapy of ccRCC via the synergistic actions of CDT and cuproptosis as well as immunotherapy.
Trends in Preeclampsia Risk Factors in the US From 2010 to 2021
Authors: Mariam K. Ayyash, Rodney McLaren, Majid Shaman, Huda B. Al-Kouatly
Journal: JAMA (2024)

This population-based retrospective study uses data from the National Vital Statistics System to evaluate trends in risk factors for preeclampsia in the US between 2010 and 2021.
Future perspectives on engineered T cells for cancer
Authors: Avery D. Posey, Regina M. Young, Carl H. June
Journal: Trends in cancer (2024)

Chimeric antigen receptor (CAR) T cell therapy has emerged as a revolutionary treatment for hematological malignancies, but its adaptation to solid tumors is impeded by multiple challenges, particularly T cell dysfunction and exhaustion. The heterogeneity and inhospitableness of the solid tumor microenvironment (TME) contribute to diminished CAR T cell efficacy exhibited by reduced cytotoxicity, proliferation, cytokine secretion, and the upregulation of inhibitory receptors, similar to the phenotype of tumor-infiltrating lymphocytes (TILs). In this review, we highlight recent advances in T cell therapy for solid tumors, particularly brain cancer. Innovative strategies, including locoregional delivery and 'armoring' CAR T cells with cytokines such as interleukin (IL)-18, are under investigation to improve efficacy and safety. We also highlight emerging issues with toxicity management of CAR T cell adverse events. This review discusses the obstacles associated with CAR T cell therapy in the context of solid tumors and outlines current and future strategies to overcome these challenges.
Targeting extranuclear histones to alleviate acute and chronic inflammation
Authors: Gerry A.F. Nicolaes, Oliver Soehnlein
Journal: Trends in Pharmacological Sciences (2024)

Extracellular histones instigate an inflammatory triad - centered on cytotoxicity, immune cell stimulation, and coagulation - ultimately shaping the dynamics and outcome of various inflammatory pathologies. Given the virtual absence of beneficial functions of histones in the extracellular space, in recent years a number of interference strategies have emerged. In this review we summarize pathogenic functions of extracellular histones and highlight current developments of therapeutic interference. Finally, we elaborate on the current status of preclinical attempts to interfere with extracellular histones in the context of a focus on sepsis and cardiovascular diseases, both of which are leading causes of mortality worldwide.
Article Changed to Open Access
Journal: JAMA Internal Medicine (2024)

Lipika Samal, MD, MPH; John L. Kilgallon, BA; Stuart Lipsitz, ScD; Heather J. Baer, ScD; Allison McCoy, PhD; Michael Gannon, ScM; Sarah Noonan, BS; Ryan Dunk, BA; Sarah W. Chen, BS; Weng Ian Chay, BS; Richard Fay, MEd; Pamela M. Garabedian, MS; Edward Wu, BS; Matthew Wien, BS; Saul Blecker, MD, MHS; Hojjat Salmasian, MD, MPH, PhD; Joseph V. Bonventre, MD, PhD; Gearoid M. McMahon, MBBCH; David W. Bates, MD; Sushrut S. Waikar, MD, MPH; Jeffrey A. Linder, MD, MPH; Adam Wright, PhD; Patricia Dykes, RN, PhD, MA
The Case for Continuing to Improve Medicare Advantage
Authors: Sachin H. Jain
Journal: JAMA Internal Medicine (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal